- Home
- SLXN vs IBG Comparison
SLXN vs IBG Comparison
Compare SLXN & IBG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLXN
- IBG
- Stock Information
- Founded
- SLXN 2008
- IBG 2018
- Country
- SLXN Israel
- IBG Australia
- Employees
- SLXN N/A
- IBG N/A
- Industry
- SLXN
- IBG Beverages (Production/Distribution)
- Sector
- SLXN
- IBG Consumer Staples
- Exchange
- SLXN NYSE
- IBG Nasdaq
- Market Cap
- SLXN 7.3M
- IBG 6.0M
- IPO Year
- SLXN N/A
- IBG 2024
- Fundamental
- Price
- SLXN $0.80
- IBG N/A
- Analyst Decision
- SLXN Strong Buy
- IBG Strong Buy
- Analyst Count
- SLXN 1
- IBG 1
- Target Price
- SLXN $5.00
- IBG N/A
- AVG Volume (30 Days)
- SLXN 141.1K
- IBG 90.0K
- Earning Date
- SLXN 08-21-2025
- IBG 07-15-2025
- Dividend Yield
- SLXN N/A
- IBG N/A
- EPS Growth
- SLXN N/A
- IBG N/A
- EPS
- SLXN N/A
- IBG N/A
- Revenue
- SLXN N/A
- IBG $2,931,243.00
- Revenue This Year
- SLXN N/A
- IBG N/A
- Revenue Next Year
- SLXN N/A
- IBG N/A
- P/E Ratio
- SLXN N/A
- IBG N/A
- Revenue Growth
- SLXN N/A
- IBG N/A
- 52 Week Low
- SLXN $0.58
- IBG $0.44
- 52 Week High
- SLXN $41.85
- IBG $3.35
- Technical
- Relative Strength Index (RSI)
- SLXN N/A
- IBG N/A
- Support Level
- SLXN N/A
- IBG N/A
- Resistance Level
- SLXN N/A
- IBG N/A
- Average True Range (ATR)
- SLXN 0.00
- IBG 0.00
- MACD
- SLXN 0.00
- IBG 0.00
- Stochastic Oscillator
- SLXN 0.00
- IBG 0.00
About SLXN BIOMOTION SCIENCES
Silexion Therapeutics Corp a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for KRAS-driven cancers. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals into the cell. Its product candidate, SIL204, consists of locally administered small interfering RNAs, or siRNA, in a solution, as a first-line treatment of locally advanced pancreatic cancer patients, or LAPC, in combination with standard-of-care chemotherapy. It is currently focused on treatment for pancreatic cancer tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected and are non-resectable, i.e. it is not able to be surgically removed.
About IBG Innovation Beverage Group Limited Ordinary Shares
Innovation Beverage Group Ltd is a developer, manufacturer, marketer, exporter, and retailer of a growing beverage portfolio of 70 formulations across 14 alcoholic and non-alcoholic brands. The company's focus is on premium and super premium brands. The Group has two reportable geographic segments: Australia and the United States.